Ocuphire Q3 net income $5.6M ($0.26 EPS); revenue $11.9M; FDA agrees Phase 3 endpoint for APX3330; RYZUMVI approved

Opus Genetics, Inc.

2023-Q3 EPS reported -$0.25 revenue$17,358,000

Q3 net income $5.6M ($0.26 basic EPS) vs $4.5M loss ($0.22 loss) a year ago; revenue $11.9M from $0.
Cash $42.4M; management believes sufficient into 2025.
Successful End-of-Phase 2 FDA meeting for APX3330; Phase 3 endpoint agreed (3-step worsening on DRSS).
RYZUMVI (phentolamine) FDA approved for mydriasis reversal; Ocuphire received $10M milestone from Viatris.
VEGA-2 Phase 3 presbyopia trial met primary endpoint; Viatris to continue Phase 3 development in 1H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Opus Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue $11.9 million.

Period: third quarter ended September 30, 2023
Revenue: $11.9 million
Result: reported results

Exact text from the filing

License and collaborations revenue was $11.9 million and $17.4 million for the three and nine months ended September 30, 2023, respectively.

View on SEC.gov

31 earnings releases filed in the last 30 days. Browse all earnings releases →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-052736

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.